- Setting up a network of experts for developing a guidance document on how to deal with human biomonitoring in PFAS hotspots
- Suggested list of biomarkers, matrices and analytical methods for the 1st prioritisation round of substances
- Suggested list of biomarkers, matrices and analytical methods for the 2nd prioritisation round of substances
- Watch Our Videos
- Europe Biobank Week 2021
- A24 Obtaining health information_13_Country example from Austria
- A24 Obtaining health information_12_Country example from Sweden
- A24 Obtaining health information_11_Record linkage
- A24 Obtaining health information_10_Case study on effect biomarkers
- A24 Obtaining health information_9_Effect biomarkers
- A24 Obtaining health information_8_Puberty development
- A24 Obtaining health information_7_Asthma-COPD-allergies
- A24 Obtaining health information_6_Anthropometrics
- A24 Obtaining health information_5_MetS and CVD
- A24 Obtaining health information_4_Country example from Germany
Disclaimer
The HBM4EU project was launched in 2016 with the aim of improving the collective understanding of human exposure to hazardous chemicals and developing HBM as an exposure assessment method. The project had €74m in funding and jointly implemented by 120 partners from 28 participating countries – 24 EU member states plus Norway, Switzerland, Iceland and Israel and the European Environment Agency. One of its aims was to ensure the sustainability of HBM in the EU beyond 2021. The project ended in June 2022. The website will not be updated any longer, except the page on peer reviewed publications, but will be online until 2032.
